Results 81 to 90 of about 56,538 (251)
Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis [PDF]
, 2019 Objectives: A new patient-reported outcome (PRO) instrument to measure fatigue symptoms and impacts in relapsing multiple sclerosis (RMS) was developed in a qualitative stage, followed by psychometric validation and migration from paper to an electronic ...
Eremenco, Sonya +5 more
core +1 more source
Systemic Acrolein Elevations in Mice With Experimental Autoimmune Encephalomyelitis and Patients With Multiple Sclerosis [PDF]
, 2018 Demyelination and axonal injury are the key pathological processes in multiple sclerosis (MS), driven by inflammation and oxidative stress. Acrolein, a byproduct and instigator of oxidative stress, has been demonstrated as a neurotoxin in experimental ...
Acosta, Glen +8 more
core +1 more source
Annals of Neurology, EarlyView.Cladribine tablets are approved for relapsing multiple sclerosis, mediating their clinical effect by moderately depleting lymphocytes. In a prospective, monocentric study including 22 patients completing 2 annual cycles of cladribine, B‐ and T‐cell receptor repertoires and relapse activity were assessed at baseline and after 24 months. T‐cell clonality
Tilman Schneider‐Hohendorf +8 more
wiley +1 more source
Patient Preference and Adherence, 2014 Matteo Caporro, Giulio Disanto, Claudio Gobbi, Chiara Zecca Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland Abstract: Glatiramer acetate, a synthetic amino acid polymer analog of myelin basic protein, is one of ...
Caporro M, Disanto G, Gobbi C, Zecca C
doaj
Predicting the On-Study Relapse Rate for Multiple Sclerosis Patients in Clinical Trials [PDF]
, 2005 Background: The annual relapse rate has been commonly used as a primary efficacy endpoint in phase III multiple sclerosis (MS) clinical trials. The aim of this study was to determine the relative contribution of different possible prognostic factors ...
Heigenhauser, L. +4 more
core +2 more sources
Advanced NanoBiomed Research, EarlyView.This review explains how biomaterials and nanoparticles can be used to induce or modulate tertiary lymphoid structures (TLSs), which are ectopic immune hubs that form in nonlymphoid tissues during chronic disease and cancer. By comparing different methods, the article highlights design principles for modeling TLSs or recapitulating specific TLS ...
Shaza Karaman, Mei ElGindi, Jeremy Teo
wiley +1 more source
Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
Journal of Central Nervous System Disease, 2011 Fingolimod was recently approved for use in the United States after two phase III trials confirmed its effectiveness in reducing disease activity in relapsing-remitting multiple sclerosis. These positive results, coupled with the important fact that this
James J. Marriott
doaj +1 more source
Neuromodulation in neurogenic bladder. [PDF]
, 2016 While neuromodulation is a well-established treatment option for patients with non-neurogenic overactive bladder and urinary retention, its applicability to the neurogenic bladder population has only recently been examined more in depth.
Sanford, Melissa T, Suskind, Anne M
core +1 more source
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
Frontiers in ImmunologyThe onset and relapse of autoimmune diseases (AIDs) are triggered by autoimmune attacks on target tissues. However, symptoms are unlikely to appear if damaged cells are rapidly replaced.
Zeev Elkoshi
doaj +1 more source